Nina Worel, 1 Nelli Frank, 2 Christian Frech, 2 and Gerhard Fritsch 2 BACKGROUND: Peripheral blood stem cells mobilized with granulocyte-colony-stimulating factor (G-CSF) with or without chemotherapy are routinely used for autologous hematopoietic cell transplantation. Plerixafor, a chemokine-receptor inhibitor, increases the amount of circulating CD341 cells and improves harvest results. However, limited information is available regarding the composition of apheresis products with respect to CD341 and lymphocyte subtypes collected after various mobilization regimens.
STUDY DESIGN AND METHODS:
We used a recently established single-platform multicolor flowcytometric analysis including CD45RA and CD133 to define CD341 subpopulations and lymphocyte subsets in products obtained either after G-CSF with or without chemotherapy alone (G, n 5 40) or with addition of plerixafor (GP, n 5 40).
RESULTS: Absolute numbers of white blood cells and lymphocyte subtypes were significantly higher after plerixafor, which was not observed for absolute CD341 counts. However, distinct differences in terms of CD341 subtypes were observed. The most primitive multipotent progenitors (CD45RA-CD1331CD341CD38 low ) predominated significantly after G (median, 49.2%; range, 15.2%-63%) compared to GP (median, 34.4%; range, 12%-62%; p < 0.001), whereas more differentiated subsets clearly prevailed after GP.
CONCLUSION:
In contrast to the findings of other authors, our study shows a clear shift toward more committed CD341 subsets after plerixafor in poor mobilizers and elucidates the importance of informative surface markers like CD45RA and CD133 in addition to CD38 to discriminate earlier from more committed CD341 cells. Further studies are needed to analyze whether these findings have an impact on clinical outcome.
A utologous hematopoietic cell transplantation (HCT) is a potentially curative treatment option for a variety of hematologic diseases and applied as part of first-or second-line therapy in multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). In addition, selected patients with solid tumors (e.g., neuroblastoma, Ewing sarcoma, germ cell cancer) may profit from autologous HCT. 1 For more than 20 years, granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSCs) have been used as preferred graft source instead of bone marrow (BM) due to a more rapid engraftment. 2 Common strategies for PBSC mobilization include the use of G-CSF alone or in combination with chemotherapy, resulting in a marked increase of CD341 cells in the peripheral blood. However, a significant proportion of patients fail to mobilize adequately. To enhance CD341 cell release from the BM, plerixafor, a chemokine receptor Type 4 (CXCR4) antagonist, can be given in addition to G-CSF with or without chemotherapy. [3] [4] [5] [6] Several authors investigated the composition of PBSC grafts after various mobilization methods. [7] [8] [9] [10] However, preanalytic methods including the use of fluorochromes and antibody combinations to characterize PBSC by flow cytometry and analysis techniques reported are different. Fruehauf and colleagues 11 described a higher frequency of "CD38-primitive stem cells" after plerixafor administration showing also CD38 dot plots. Most of the other authors did not provide information about gating strategies but also reported higher proportions of CD38-/CD341 cells after plerixafor compared to G-CSF alone. [8] [9] [10] 12, 13 In addition, Taubert and coworkers 14 found increased proportions of CD38-cells after plerixafor mobilization and reported higher CD133 mRNA levels in CD341/ALDH bright cells. Based on recent studies describing a revision of the hematopoietic tree, 15, 16 we established a multicolor single-platform analysis to enumerate CD34 subtypes of stem cell grafts. 17 The earliest CD34 subset, the multipotent progenitors (MPPs), represents CD341 cells, which are part of the CD45RA2CD1331CD38 low CD102 subfraction. Tracking CD133 segregation in functional single-cell analyses, it was shown that MPPs create pairs of daughter cells, a lymphoidprimed multipotent (LMPP) and an erythromyeloid progenitor (EMP). 18 Whereas LMPPs up regulate CD45RA and retain CD1331 (CD45RA1CD1331CD38 low CD102), EMPs retain CD45RA2 but lose CD133 expression (CD45RA2 CD1332 /low CD381CD102). LMPPs harbor the potential to create neutrophil and macrophage progenitors (GMPs) and multilymphoid precursors (MLPs) that start to express CD10. Differentiation of MLPs toward the CD341CD191 Bcell progenitors (BLPs; CD45RA1CD1332CD3811CD101) is accompanied by loss of CD133 and increased CD38 expression (Fig. 1) . Based on the definition of these subsets, we recently described distinct differences between autologous PBSCs, allogeneic BM grafts, and BM samples of patients 1 year after allogeneic HCT. 17 In this study we used our recently established multicolor immune-phenotyping method to define and enumerate CD34 and lymphocyte subpopulations in 80 autologous PBSC grafts collected either after G-CSF with or without chemotherapy mobilization only (G) or after the addition of plerixafor (GP).
MATERIALS AND METHODS

Patients and specimens
Eighty patients (51 males/29 females) were included in the study. Diagnoses consisted of MM (n 5 49), NHL (n 5 22), Hodgkin's disease (n 5 4), germ cell cancer (n 5 3), and Ewing sarcoma (n 5 2). Patients in the G group were mobilized either with G-CSF alone (n 5 20) or /L, the CD341 count remained fewer than 20 3 10 6 cells/L and no further increase was expected. All patients received plerixafor at a dose of 240 mg/kg subcutaneously, between 6 and 11 hours before start of leukapheresis. The specimens used in this study were obtained for routine CD34 enumeration of PBSC grafts. Informed consent was obtained from all patients and the extended staining experiments had been approved by the local ethical committee. Only the first leukapheresis product of each patient was included in this study. Patient characteristics are shown in Table 1 .
Flow cytometry
Blood cell counts were obtained from a hematology analyzer (KX-21N, Sysmex Corporation). Samples were diluted with Dulbecco's phosphate-buffered saline (Life Technologies) to adjust WBC numbers to fewer than 40 3 10 9 cells/L before immune staining. All monoclonal antibodies (MoAbs) were used at pretested concentrations, and compensations had been set accordingly. Isotype controls and fluorescence-minus-one analyses were used to define gating and compensation. Analyses were performed on a flow cytometer (FACS Fortessa, BD Biosciences) equipped with four solid-state lasers with excitation wave lengths (nm) of 488, 405, 561, and 640. Quality controls were performed at least once weekly with research beads (CS&T, BD Biosciences). Computer software (FACSDiVa 6, BD Biosciences) was used for data acquisition and evaluation. For each analysis 150,000 CD451 events were acquired.
Single platform protocol
The MoAb cocktail for defining the CD341 subpopulations contained CD7 PeCF594, CD10 BV421, CD33 APC-R700, CD38 PE-Cy7, CD45RA BV510 (all from BD Biosciences), CD3 PerCPeFl710 (eBiosciences), CD19 APC-Cy7 (BD PharMingen), and AC133-1 APC (Miltenyi Biotec; see Table S1 [available as supporting information in the online version of this paper] for detailed antibody cocktail composition). For CD341 subgroup analyses, 100 mL of the cell sample was reverse-pipetted into a tube (Trucount, BD Biosciences). After the stem cell enumeration kit (20 mL of 7-AAD and 20 mL of CD45 FITC/CD34 PE; BD Biosciences) and the MoAb cocktail (25.5 mL) were added, cells were mixed and incubated light-shielded at room temperature (20-258C) for 20 minutes. Red blood cells (RBCs) were lysed by adding 2 mL of ammonium chloride solution (BD Biosciences) for 10 minutes before samples were analyzed.
The MoAb cocktail for defining lymphocyte subsets comprised CD19 BV510, TCR-cd PE, CD45 PerCP, CD56 PE-Cy7, and CD8 APC-Cy7 (all from BD Biosciences), TCR-ab FITC and CD3 PE-Texas Red (both from BD PharMingen), and CD4 PerCP e-FL710 and CD16 APC (both from eBiosciences; Table S1 ). For analyses of lymphocytes, 10 mL of the cell sample was reverse-pipetted into a tube (Trucount, BD Biosciences). After 8.3 mL of the MoAb cocktail was added, cells were mixed, incubated lightshielded at room temperature for 20 minutes, and then diluted 1:10 with ammonium chloride solution (BD Biosciences). After RBC lysis, samples were analyzed.
Gating strategy
To define CD341 cells and their subsets, we used the gating strategy described previously. 17 Briefly, viable and true hematopoietic progenitor cells (HPCs) were determined by their positivity for CD34, their weak expression of CD45, their typical position in the lymphomonocytic area of the forward scatter/side scatter (FSC/SSC) dot plot and their negativity for 7-AAD. 19 CD34 subtyping was started with CD45RA, as this marker allows the definition of two distinct subgroups separating earlier CD45RA2 from more committed CD45RA1 cells. These subpopulations were then further evaluated in CD133 versus CD10 contour plots where they formed at least six distinct CD34 subpopulations (see Fig. S1 [available as supporting information in the online version of this paper] for gating strategy of CD341 subsets). The resulting subpopulations were examined for their expression of CD38. Beads were double-gated in two different dot plots (APC vs. SSC and APC-Cy7 vs. FITC) to exclude false-positive events. The gating strategy for lymphocyte subsets was identical to the method described elsewhere. 20 Briefly, viable 
Statistical analyses
Computer software (R version 3. Fig. 2 ). Basis for CD34 subtype frequencies are viable CD341 cells, whereas all CD341 cells as well as lymphocyte subsets are expressed as percentage of viable WBCs. The mean frequency of CD341 cells was higher in the G than the GP group (1.16% 6 1.4% vs. 0.62% 6 0.6%; p < 0.01) but there was no significant difference in absolute CD341 cell numbers (7.01 3 10 6 6 5.9 3 10 6 /kg vs. 5.82 3 10 6 6 4.9 3 10 6 /kg; Table 1 , Fig. 2A ). Considerable differences between the two groups regarding the composition of CD34 subtypes were observed for both relative values and absolute cell numbers (Table 1, Fig. 2B ). The mean proportion of the most primitive stem cell (CD45RA-CD1331CD38 low CD10-) was significantly higher in products obtained after mobilization with G (46.98% 6 10.4%) compared to GP (36.85% 6 12.8%; p < 0.001). As a consequence, absolute MPP numbers were also significantly higher in the G than in the GP group ( /kg; p < 0.05). contains 95% of data points in a normally distributed sample. For total CD341 cells (A), absolute numbers (left box) were not different between PBSCs collected in the G (gray dots) and in the GP group (black dots), whereas relative values (right box) were higher in the G than in the GP group. For CD34 subgroups (B), absolute numbers (upper graph) of MPPs and EMPs were significantly higher in the G group (gray dots), while late GMPs and MLPs including BLPs were significantly higher in the GP cohort (black dots). Relative values (C) of MPPs and EMPs were also significantly higher in the G group (gray dots). This was in contrast to LMPPs, late GMPs, and MLPs including the more mature BLP subsets, which were clearly more frequent in the GP group (black dots).
Due to the low frequency of CD1331 MLPs (CD45RA1CD1331CD381CD101), this CD34 subset was evaluated together with the CD1332 BLPs (CD45RA1 CD133-CD3811CD101CD191). These cells were barely detectable in products obtained after G (1.94% 6 2%; 0.11 3 10 6 6 0.1 3 10 6 /kg) but clearly present after GP mobilization (6.53% 6 7.6%; 0.35 3 10 6 6 0.5 3 10 6 /kg; p < 0.001 and p < 0.01). The late GMPs (CD45RA1 CD1332CD381CD102) were significantly lower after mobilization with G than GP for relative (2.19% 6 2.5% vs. 7.88% 6 5.9%; p < 0.001) and absolute values (0. 16 In all experiments, we used the PE-Cy7-labeled H7 clone of CD38. Virtually all CD341 cells were positive for this antibody, but at clearly different intensities, as shown previously. 17 MPPs showed the lowest CD38 expression intensity. These progenitors either differentiate into LMPPs acquiring CD45RA or lose CD133 expression and become EMP. Both LMPPs and EMPs show a higher mean CD38 expression than MPPs, reflecting their more mature state. However, the increase in mean fluorescence intensity (MFI) is more pronounced in EMPs than in LMPPs (Fig. 3) . The intensity was higher among CD45RA1 late GMPs (Fig.  3) and highest among the CD45RA1CD101CD191 BLPs (data not shown). Due to the considerable overlap between the different CD34 subgroups, CD38 was never used as first-line antibody for subgroup discrimination. In terms of lymphocyte subsets, we observed major differences in absolute cell numbers per kg body weight between the GP and the G groups. /kg; p < 0.05) were significantly higher after GP mobilization, whereas CD4 cells showed only a trend toward higher numbers in the GP cohort (p 5 0.05). The significantly higher cell numbers after GP stimulation were a result of the clearly higher total WBCs, but not of cell frequency in any of the lymphocyte subgroups (Table 1) .
DISCUSSION
Plerixafor, an a-CXCR4 antagonist, has shown to be an effective mobilizing agent for patients with MM and malignant lymphoma. The addition of plerixafor to G-CSF allows successful CD34 collection in the majority of patients who failed previous mobilization or are classified as poor mobilizers. 3, 5, [21] [22] [23] [24] [25] Only few authors characterized CD34 subtypes mobilized by different mobilization regimens. Fruehauf and colleagues 11 observed a higher proportion of CD38 dim progenitor cells after GP compared to G stimulation and documented the results in CD38 versus CD133 dot plots. Since low CD38 expression on CD341 cells has been known for many years to correlate with an early stage of CD34 differentiation, 26 the authors concluded that plerixafor mobilizes more "primitive" progenitors than G-CSF alone. Subsequent reports showed similar results. However, none of these groups described their gating strategies or showed figures depicting how "CD38 dim " "CD38 low " or "CD38 negative " cells had been defined. [8] [9] [10] 13 Various groups 16, 27 have developed the Fig. 3 . Contour plots of selected CD34 subpopulations labeled with CD38. This figure shows the CD38 expression patterns of distinct CD34 subsets defined by CD45RA and CD133 gating as described in Fig. S1 . The "primitive stem cells" previously described by others 11 as CD1331 and CD38 low had been defined without CD45RA and thus represent a mixture of both MPPs and LMPPs (second and third plots). The lower level of CD38 expression (black line) is similar for these two subsets. This becomes obvious after separate gating of the CD1331CD45RA1 LMPPs generated by differentiation from CD1331CD45RA-MPPs. The CD133-subsets "late GMPs" (CD45RA1) and EMPs (CD45RA-) display a clearly higher CD38 expression.
model of a hematopoietic tree, describing the differentiation from the earliest CD341 MPPs to lineage-committed CD341 precursors giving rise to defined blood cells. Based on this work, we previously established a multicolor single-platform flow-cytometric assay to define at least six distinct CD34 progenitor subsets in different CD34 cell sources. 17 According to this analysis and a second antibody panel defining lymphocyte subsets, 20 we analyzed PBSC grafts obtained after either G-CSF with or without chemotherapy without (n 5 40) or with (n 5 40) the addition of plerixafor, to investigate potential differences between these two mobilization regimens. Interestingly, our analyses show that plerixafor mobilizes more mature CD341 progenitors than G-CSF alone. In contrast, G-CSF alone leads to significantly higher relative and absolute numbers of the most primitive progenitors (MPPs) compared to plerixafor. The relative proportion of cells contained in the LMPP fraction, which still express CD133 like MPPs, but have developed toward a CD45RA1 stage, thus giving rise to neutrophil and B-cell precursors, is significantly higher in products of the GP group. In addition, grafts of the G group contain significantly higher numbers of EMPs, harboring precursors of RBCs, megakaryocytes, eosinophils, and basophils. Moreover, significant differences in favor of plerixafor were observed for the most differentiated progenitors, the late GMP and the B-cell precursors (p < 0.001). Previously a study by Donahue and coworkers 28 revealed that plerixafor mobilizes a greater proportion of stem cells, which are more likely to be committed toward B, T, and mast cells. They also suggest that plerixafor plus G-CSF mobilizes a larger proportion of B-and T-cell precursors than G-CSF alone. More recently another study by Schroeder and coworkers 29 conducted in healthy stem cell donors found that G-CSF mobilizes more CD45RA-primitive hematopoietic stem cells, and plerixafor mobilizes more committed CD341CD45RA1CD12311 stem cells. Our results are in contrast to previous reports showing an increase of "primitive progenitors" after mobilization with plerixafor. Fruehauf and coworkers 11 found 0.9% of CD341 cells to be CD1331CD38 low after G, but 2.6% after GP. All subsequent reports described similar results, ranging from between 0.6 and 1.8% after G to 2.6 and 8% after GP. 7 We assume that the reason for this discrepancy is caused by the fact that CD38 was used in combination with CD133 or even alone to define primitive progenitors, but not in a combination with CD133 and CD45RA. However, only the latter combination allows separation of early CD1331CD45RA-MPP from more committed CD1331CD45RA1 LMPPs. 15, 17, 18 In contrast to MPPs, LMPPs are positive for CD45RA (Fig. S1D) , but still show a low expression of CD38 (Fig. 3 ) and may therefore be confounded with "primitive" CD34 cell stages if CD45RA is not included in the analysis. Therefore, CD38 alone cannot, by any means, be used to define early CD341 progenitors. [8] [9] [10] [11] [12] 14, 30 The overlapping CD38 expression profiles of different CD34 subsets are described in Fig. 3 . This fact was also addressed previously where CD133 was used in combination with CD38. The authors argued that analyzing the CD38 MFI might "blur changes in the CD341CD38-subset." 11 With regard to frequencies of CD341CD38-stem cell subsets our findings are in line with a recently published study analyzing grafts from 139 NHL patients after mobilization with G-CSF alone. 31 This study shows that stem cell grafts contained a relatively high amount of primitive CD341CD38-cells (52%-55%). These findings are comparable to our results detected in the G group (mean percentage of MPPs, 49.2%). In this study, we have not analyzed products obtained from patients who eventually received plerixafor for a second apheresis procedure in case of poor mobilization or collection results after G-CSF alone. However, we have observed a decrease of MPPs and an increase of LMPPs in patients not included in this study who received plerixafor for a subsequent harvest procedure (Fig. 4) . We found significantly higher absolute numbers of CD31, CD81, CD191, and NK cells in products obtained after plerixafor, whereas the frequencies did not differ between the GP and G groups. These findings go in line with previously published reports. 7, 9, 10, 30 As CXCL12/CXCR4 chemokine signaling controls T-and NK-cell trafficking, plerixafor may be able to overcome CXCR4 retention in the BM niche. 7, 32 The question whether or not a higher amount of immune cells in autologous stem cell grafts has an impact on overall and disease-free survival has so far not been answered consistently. Most of the studies were performed retrospectively and show controversial data. 9, 10, [33] [34] [35] [36] Of note, a higher number of T lymphocytes and NK cells infused with the graft correlates with a more rapid immune recovery after autologous HCT. 7, 37, 38 In this study, the impact of two different mobilization strategies was analyzed only with respect to graft composition.
One major limitation of our study is that only patients who presented as poor mobilizers received plerixafor but none of the good mobilizing patients. Therefore, our findings might also be related to an impaired BM reserve or function in poor mobilizers. To answer this question, a prospective randomized trial in a patient cohort composed of good mobilizers should be conducted.
In conclusion, stem cell graft composition is still ambiguous and little is known about the impact of different CD34 and lymphocyte subtypes on hematopoietic and immune recovery and clinical outcome. To evaluate a possible influence on clinical outcome, prospective randomized trials are warranted. Up to now the only validated variable for quality of stem cell grafts remains the CD341 cell dose. Due to the introduction of novel mobilizing agents and advances in laboratory techniques, the assessment of graft composition can be expected to lead to better knowledge and the development of other predictors for clinical outcome. In light of the new perceptions of flow cytometric analyses of CD34 subsets, grafts obtained after different mobilization regimens should be analyzed carefully to allow precise interpretation of these data. Further studies will show whether or not the newly introduced analyses can contribute to this field.
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